CDIO

Company Overview — What Does Cardio Diagnostics Holdings, Inc. Do?

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware. Cardio Diagnostics Holdings, Inc. (CDIO) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Meeshanthini Dogan and employs approximately 1 people. With a market capitalization of $6M, CDIO is one of the notable companies in the Healthcare sector.

Cardio Diagnostics Holdings, Inc. (CDIO) Stock Rating — Avoid (April 2026)

As of April 2026, Cardio Diagnostics Holdings, Inc. receives a Avoid rating with a composite score of 24.5/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CDIO ranks #4,246 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cardio Diagnostics Holdings, Inc. ranks #766 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CDIO Stock Price and 52-Week Range

Cardio Diagnostics Holdings, Inc. (CDIO) currently trades at $1.88. The stock gained $0.07 (3.9%) in the most recent trading session. The 52-week high for CDIO is $7.91, which means the stock is currently trading -76.2% from its annual peak. The 52-week low is $0.15, putting the stock 1153.3% above its annual trough. Recent trading volume was 68K shares, suggesting relatively thin trading activity.

Is CDIO Overvalued or Undervalued? — Valuation Analysis

Cardio Diagnostics Holdings, Inc. (CDIO) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.86x, versus the sector average of 2.75x. The price-to-sales ratio is 336.57x, compared to 1.66x for the average Healthcare stock.

At current multiples, Cardio Diagnostics Holdings, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cardio Diagnostics Holdings, Inc. Profitability — ROE, Margins, and Quality Score

Cardio Diagnostics Holdings, Inc. (CDIO) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -92.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -83.0% versus the sector average of -33.1%.

On a margin basis, Cardio Diagnostics Holdings, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -69321.3% (sector: -66.1%). Net profit margin stands at -69495.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -63.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CDIO Debt, Balance Sheet, and Financial Health

Cardio Diagnostics Holdings, Inc. has a debt-to-equity ratio of 11.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 9.79x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $6M.

CDIO has a beta of 7.34, meaning it is more volatile than the broader market — a $10,000 investment in CDIO would be expected to move 633.6% more than the S&P 500 on any given day. The stability factor score for Cardio Diagnostics Holdings, Inc. is 3/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Cardio Diagnostics Holdings, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cardio Diagnostics Holdings, Inc. reported revenue of $17,850 and earnings per share (EPS) of $-3.71. Net income for the quarter was $-6M. Gross margin was 100.0%. Operating income came in at $-6M.

In FY 2025, Cardio Diagnostics Holdings, Inc. reported revenue of $14,825 and earnings per share (EPS) of $-3.71. Net income for the quarter was $-6M. Revenue grew -57.5% year-over-year compared to FY 2024. Operating income came in at $-6M.

In Q3 2025, Cardio Diagnostics Holdings, Inc. reported revenue of $2,855 and earnings per share (EPS) of $-0.98. Net income for the quarter was $-2M. Revenue grew -56.6% year-over-year compared to Q3 2024. Operating income came in at $-2M.

In Q2 2025, Cardio Diagnostics Holdings, Inc. reported revenue of $7,475 and earnings per share (EPS) of $-0.97. Net income for the quarter was $-2M. Revenue grew -5.0% year-over-year compared to Q2 2024. Operating income came in at $-2M.

Over the past 8 quarters, Cardio Diagnostics Holdings, Inc. has demonstrated a growth trajectory, with revenue expanding from $7,870 to $17,850. Investors analyzing CDIO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CDIO Dividend Yield and Income Analysis

Cardio Diagnostics Holdings, Inc. (CDIO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CDIO Momentum and Technical Analysis Profile

Cardio Diagnostics Holdings, Inc. (CDIO) has a momentum factor score of 50/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 15/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

CDIO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cardio Diagnostics Holdings, Inc. (CDIO) ranks #766 out of 838 stocks based on the Blank Capital composite score. This places CDIO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CDIO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CDIO vs S&P 500 (SPY) comparison to assess how Cardio Diagnostics Holdings, Inc. stacks up against the broader market across all factor dimensions.

CDIO Next Earnings Date

No upcoming earnings date has been announced for Cardio Diagnostics Holdings, Inc. (CDIO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CDIO? — Investment Thesis Summary

The quantitative profile for Cardio Diagnostics Holdings, Inc. suggests caution. The quality score of 16/100 flags below-average profitability. The value score of 10/100 indicates premium valuation. High volatility (stability score 3/100) increases portfolio risk.

In summary, Cardio Diagnostics Holdings, Inc. (CDIO) earns a Avoid rating with a composite score of 24.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CDIO stock.

Related Resources for CDIO Investors

Explore more research and tools: CDIO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CDIO head-to-head with peers: CDIO vs AZN, CDIO vs SLGL, CDIO vs VMD.